APA

Lehner Z., Stadlbauer K., Adorjan I., Rustenbeck I., Belz M., Fenzl A., de Cillia V. A. M., Gruber D., Bauer L., Frobel K., Brunmair B., Luger A. & Fürnsinn C. (20130226). Mechanisms of antihyperglycaemic action of efaroxan in mice: time for reappraisal of α2A-adrenergic antagonism in the treatment of type 2 diabetes?. : Diabetologia.

Chicago

Lehner Z, Stadlbauer K, Adorjan I, Rustenbeck I, Belz M, Fenzl A, de Cillia V A M, Gruber D, Bauer L, Frobel K, Brunmair B, Luger A and Fürnsinn C. 20130226. Mechanisms of antihyperglycaemic action of efaroxan in mice: time for reappraisal of α2A-adrenergic antagonism in the treatment of type 2 diabetes?. : Diabetologia.

Harvard

Lehner Z., Stadlbauer K., Adorjan I., Rustenbeck I., Belz M., Fenzl A., de Cillia V. A. M., Gruber D., Bauer L., Frobel K., Brunmair B., Luger A. and Fürnsinn C. (20130226). Mechanisms of antihyperglycaemic action of efaroxan in mice: time for reappraisal of α2A-adrenergic antagonism in the treatment of type 2 diabetes?. : Diabetologia.

MLA

Lehner Z, Stadlbauer K, Adorjan I, Rustenbeck I, Belz M, Fenzl A, de Cillia V A M, Gruber D, Bauer L, Frobel K, Brunmair B, Luger A and Fürnsinn C. Mechanisms of antihyperglycaemic action of efaroxan in mice: time for reappraisal of α2A-adrenergic antagonism in the treatment of type 2 diabetes?. : Diabetologia. 20130226.